-
1 Comment
Cyclopharm Limited is currently in a long term downtrend where the price is trading 34.4% below its 200 day moving average.
From a valuation standpoint, the stock is 94.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.3.
Cyclopharm Limited's total revenue rose by 17.6% to $9M since the same quarter in the previous year.
Its net income has dropped by 451.4% to $-394K since the same quarter in the previous year.
Finally, its free cash flow fell by 118.9% to $-3M since the same quarter in the previous year.
Based on the above factors, Cyclopharm Limited gets an overall score of 2/5.
| Sector | Healthcare |
|---|---|
| Industry | Medical Distribution |
| Exchange | AU |
| CurrencyCode | AUD |
| ISIN | AU000000CYC5 |
| Market Cap | 130M |
|---|---|
| PE Ratio | None |
| Target Price | 2.6793 |
| Beta | 0.86 |
| Dividend Yield | None |
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CYC.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
